Peptide News Digest

#Priavoid

1 story

Clinical Trials · View digest

Priavoid's Oral D-Peptide PRI-002 Missed Its Main Alzheimer's Goal at 48 Weeks in the 304-Patient PRImus-AD Trial

In people aged 55 to 80 with mild cognitive impairment or mild dementia due to Alzheimer's, daily PRI-002 at 300 mg or 600 mg did not beat placebo on the CDR-SB scale at week 48, Priavoid said at the CTAD conference in Boston on November 17. The company pointed to trends at week 72, such as 26.7% slower decline on ADAS-Cog13 (p=0.102), but most were not statistically significant. The drug met its safety endpoint. Brain swelling (ARIA-E) occurred in 2% or fewer patients in each group, and small brain bleeds (ARIA-H) in 8% and 11.7% on the two doses versus 5% on placebo, though a safety board stopped close central MRI checks for ARIA after the first 90 patients reached 24 weeks.